Neumora Therapeutics (NMRA) Other Working Capital Changes (2022 - 2026)

Neumora Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$67000.0 for Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 92.68% year-over-year to -$67000.0; the TTM figure through Mar 2026 stood at -$1.0 million (up 70.44% YoY), while the FY2025 annual figure was -$1.9 million, up 44.35% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$67000.0, up from -$1.9 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $9.7 million in Q2 2024, with the low at -$17.7 million in Q3 2024.
• The 5-year median for Other Working Capital Changes is $90500.0 (2025), against an average of -$93642.9.
• Peak annual rise in Other Working Capital Changes reached 217.88% in 2025, while the deepest fall reached 116.46% in 2025.
• Neumora Therapeutics' Other Working Capital Changes stood at $6.2 million in 2022, then tumbled by 114.61% to -$913000.0 in 2023, then climbed by 2.19% to -$893000.0 in 2024, then plunged by 116.46% to -$1.9 million in 2025, then jumped by 96.53% to -$67000.0 in 2026.
• Business Quant data shows NMRA's Other Working Capital Changes at -$67000.0 in Q1 2026, -$1.9 million in Q4 2025, and -$1000.0 in Q3 2025.